RARE DISEASERESEARCH ATLAS

ORPHA:289857

Neonatal glycine encephalopathy

high confidenceSubtype of disorder

Also known as: Classic glycine encephalopathy · Neonatal NKH · Neonatal non-ketotic hyperglycinemia

Publications

45

33.9th percentile

Trials

0

Interventional, condition-specific

Researchers

285

Distinct authors in sample

Gene link

Readiness

1/6

Stages with a signal

Clinical definition (Orphanet)

glycine is a frequent, usually severe form of glycine (GE) characterized by coma, apnea, , seizure and myoclonic jerks in the period, and subsequent .

How rare: How common this is has not been clearly measured.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (3)

classic glycine encephalopathy · neonatal NKH · neonatal non-ketotic hyperglycinemia

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

1/6 stages with a signal

Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    45 matched papers (16 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialNot found

    No matched interventional trial under our ClinicalTrials.gov rules

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

45

45 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

45 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

16 in the last 10 years · high confidence · 33.9th percentile (publications denominator)

Phrase hits: 45 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

285

Distinct author names in 45 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Aydemir C2 papers · 2008
    Papers in Europe PMC
  2. 02
    Balasubramaniam S2 papers · 2019

    Metabolic Unit, Department of Rheumatology/Metabolic Medicine, Princess Margaret Hospital, Perth, WA, Australia; School of Paediatrics and Child Health, University of Western Australia, WA, Australia.

    Papers in Europe PMC
  3. 03
    Bas AY2 papers · 2008
    Papers in Europe PMC
  4. 04
    Coskun T2 papers · 2008
    Papers in Europe PMC
  5. 05
    Demirel N2 papers · 2008

    Department of Neonatology, Dr Sami Ulus Children's Hospital, Ankara, Turkey.

    Papers in Europe PMC
  6. 06
    Kalkanoglu S2 papers · 2008
    Papers in Europe PMC
  7. 07
    Kava MP2 papers · 2019

    School of Paediatrics and Child Health, University of Western Australia, WA, Australia; Department of Paediatric Neurology, Princess Margaret Hospital for Children, Perth, WA, Australia.

    Papers in Europe PMC
  8. 08
    Ugarte M2 papers · 2023

    Centro de Diagnóstico de Enfermedades Moleculares, Centro de Biología Molecular Severo Ochoa, CBM-CSIC, Departamento de Biología Molecular, Institute for Molecular Biology-IUBM, Universidad Autónoma Madrid, CIBERER, IDIPAZ, 28049 Madrid, Spain.

    Papers in Europe PMC
  9. 09
    Zenciroglu A2 papers · 2008

    Department of Neonatology, Sami Ulus Children's Hospital, Ankara, Turkey. aysegulz@med.unc.edu

    Papers in Europe PMC
  10. 10
    Achleitner MT1 paper · 2023

    University Children's Hospital, Salzburger Landeskliniken (SALK) and Paracelsus Medical University (PMU), Salzburg, Austria.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).

Data as of 27 July 2026

No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.

high confidence · 36.5th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

Broader category glycine encephalopathy also has no matched interventional trial. See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.

Broader category: glycine encephalopathy

0

Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.

Parent-category matching found a broader label but no interventional trials under it. How we count trials.

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Neonatal glycine encephalopathy" OR "Classic glycine encephalopathy" OR "Neonatal NKH" OR "Neonatal non-ketotic hyperglycinemia"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Neonatal glycine encephalopathy" OR "Classic glycine encephalopathy" OR "Neonatal NKH" OR "Neonatal non-ketotic hyperglycinemia"

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Parent-category trials query:

"glycine encephalopathy"

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-27T12:18:07.001Z